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Multifaceted roles of GSK-3 and Wnt/b-catenin in hematopoiesis
and leukemogenesis: opportunities for therapeutic intervention
JA McCubrey1, LS Steelman1, FE Bertrand2, NM Davis1, SL Abrams1, G Montalto3, AB D’Assoro4, M Libra5, F Nicoletti5, R Maestro6,
J Basecke7,8, L Cocco9, M Cervello10 and AM Martelli9,11
Glycogen synthase kinase-3 (GSK-3) is well documented to participate in a complex array of critical cellular processes. It was initially
identiﬁed in rat skeletal muscle as a serine/threonine kinase that phosphorylated and inactivated glycogen synthase. This
versatile protein is involved in numerous signaling pathways that inﬂuence metabolism, embryogenesis, differentiation, migration,
cell cycle progression and survival. Recently, GSK-3 has been implicated in leukemia stem cell pathophysiology and may be an
appropriate target for its eradication. In this review, we will discuss the roles that GSK-3 plays in hematopoiesis and leukemogenesis
as how this pivotal kinase can interact with multiple signaling pathways such as: Wnt/b-catenin, phosphoinositide 3-kinase
(PI3K)/phosphatase and tensin homolog (PTEN)/Akt/mammalian target of rapamycin (mTOR), Ras/Raf/MEK/extracellular
signal-regulated kinase (ERK), Notch and others. Moreover, we will discuss how targeting GSK-3 and these other pathways can
improve leukemia therapy and may overcome therapeutic resistance. In summary, GSK-3 is a crucial regulatory kinase interacting
with multiple pathways to control various physiological processes, as well as leukemia stem cells, leukemia progression and
therapeutic resistance. GSK-3 and Wnt are clearly intriguing therapeutic targets.
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GSK-3 IS IMPORTANT IN DIVERSE DISEASES
Glycogen synthase kinase-3 (GSK-3) is a serine (S)/threonine(T)
kinase. It was initially identiﬁed in rat skeletal muscle as a kinase
that phosphorylated and inactivated glycogen synthase (GS). GS is
the last enzyme in glycogen biosynthesis.1–2 Obviously, one of
the initially identiﬁed roles of GSK-3 was in metabolism. Aberrant
activity of GSK-3 has also been implicated in the pathologies
of many diseases and disorders such as metabolic disorders
(diabetes, atherosclerosis, heart disease), neurological dis-
orders (Parkinson’s, Alzheimer’s, amyotrophic lateral sclerosis,
schizophrenia, bipolar disorder, mood disorders), cancer and
aging (cellular senescence, cancer stem cells, control of stem cell
pluripotency and differentiation), immune disorders and other
maladies among others.3–7 GSK-3 may be a key therapeutic target
for leukemia and other diseases because of the diversity of
pathways with which it interacts (Wnt/b-catenin, PI3K/PTEN/Akt/
mTORC1, Ras/Raf/MEK/ERK, Hedgehog (Hh), Notch and others).8–22
Aberrant GSK-3 expression has also been observed in cancers
that are resistant to radiotherapy, chemotherapy and targeted
therapy.5 Targeting GSK-3 has been shown to increase
the sensitivity of resistant cells to certain drugs and other
small-molecule inhibitors.6,7
GSK-3 FAMILY OF KINASES
GSK-3 gene family consists of two highly conserved kinases:
GSK-3a and GSK-3b. GSK3A encodes a protein of 51 kDa, whereas
GSKB encodes a protein of 47 kDa.23 GSK-3a has a glycine-rich
extension at its amino terminus. GSK-3a and GSK-3b share 98%
sequence identity in their kinase domains but 36% identity in their
carboxyl terminus.24 Both GSK-3a and GSK-3b are active in
nonstimulated cells. GSK-3s have preferences for primed
substrates; this means they prefer substrates that have already
been phosphorylated by other kinases.
REGULATION OF GSK-3 ACTIVITY BY PHOSPHORYLATION
GSK-3a and GSK-3b are ubiquitously expressed and highly
conserved. GSK-3b phosphorylates more than 40 proteins
including over 12 transcription factors.25 They are both
inactivated by diverse stimuli and signaling pathways. GSK-3a
is inactivated by phosphorylation at S21, whereas GSK-3b is
inactivated by phosphorylation at S9. These modiﬁcations inhibit
the GSK-3s by inducing a pseudosubstrate conformation in the
GSKs, which is the interaction of S21 and S9 residues with
the substrate docking motif of GSK-3a and GSK-3b, respectively.24
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S9 phosphorylation of GSK-3b results in its inactivation by
proteosomal degradation and has been associated with many
pathological conditions. Diverse kinases can phosphorylate
GSK-3b at S9 including protein kinase A, protein kinase B (also
known as Akt), p90 ribosomal S6 kinase (p90Rsk) and p70
ribosomal S6 kinase (p70S6K).23–26
Insulin signaling causes inactivation of GSK-3b (S9) and GSK-3a
(S21) by activated Akt.23–26 Epidermal growth factor, platelet-
derived growth factor and certain other growth factors also
cause inactivation of GSK-3b (S9) and GSK-3a (S21) by activated
Raf/MEK/ERK/p90Rsk1 signaling. Multiple signaling pathways may
mediate the phosphorylation and inactivation of GSK-3b and
GSK-3a by phosphorylation at S9 and S21, respectively.23–26
GSK-3b activity is also regulated by phosphorylation at tyrosine
(Y) 216. Some scientists have suggested that this is due to
autophosphorylation.27 The corresponding residue in GSK-3a is
Y279. Phosphorylation of GSK-3b at Y216 is believed to be
constitutive in resting cells.27 The biochemical roles of
phosphorylation of GSK-3b at Y216 are not clear. Apoptotic
stimuli can increase GSK-3b phosphorylation at Y216, suggesting
roles for GSK-3b in apoptosis.28,29 Some studies have suggested
that proline-rich tyrosine kinase 2 (PYK2) may phosphorylate
GSK-3s at Y216 and Y270.30 This may serve to activate GSK-3 in
certain biochemical situations. PYK2 has been shown to control
lysophosphatidic acid-induced activation of GSK-3 that leads to
the phosphorylation of microtubule-associated proteins. The Fyn
tyrosine kinase is another kinase that may phosphorylate GSKs.31
The p38 mitogen-activated protein kinase can phosphorylate
GSK-3b at S389/T390.32 Extracellular signal-regulated kinase (ERK)
may phosphorylate GSK-3b at T43, promoting a conformational
change resulting in altering its activity.25 There may also be
protein phosphatases (for example, PP2A, PP1) that play important
roles in the regulation of GSK-3 activity by removing the
phosphate on S9.33 In addition, GSK-3 may have protein
phosphatases as substrates (for example, PP1G).25
TARGETS AND FUNCTIONS OF GSK-3
GSK-3 can alter the activity of p70S6K and cellular proliferation.34
The mammalian GSK-3 homolog Mck1 can inhibit the activity of
the major mitotic cyclin–Cdk complex Clb2–Cdk1 and affect
cellular division.35
Inhibition of GSK-3 resulted in activation of p27Kip-1 and induced
cell cycle arrest at the G1 phase.
36 GSK-3 phosphorylated p21Cip1 at
T57 that led to its proteasomal degradation.37 Inactive GSK-3
prevented phosphorylation of cyclin D1 at T286 and cyclin E at
S380. This prevented their nuclear export and degradation.38,39
GSK-3 has many effects on cell growth, some of which are
indirect. As GSK-3 can regulate the activity of transcription factors,
it has profound regulatory roles on cellular proliferation.40 Growth
arrest and DNA damage-inducible 45 (GADD45) and GADD153
encode tumor suppressors and checkpoint inhibitors. GSK-3b can
regulate the activity of p53 that can, in turn, control GADD45
transcription. GADD45 can be induced by DNA damage and its
expression is controlled by p53. When GADD45 is induced, the cell
cycle is arrested. GSK-3b can also regulate the activity of c-Myc
that, in turn, can modulate the expression of the GADD45 and
GADD153 genes. c-Myc can also control the expression of cell
division cycle 25A (CDC25), which is also an important cell cycle
regulator.40 GSK-3 also controls the activity of the transcription
factors such as (nuclear factor-kB (NF-kB).40 The focal adhesion
kinase is regulated by NF-kB and GSK-3.41
GSK-3b expression can also play roles in the regulation of
apoptotic and anti-apoptotic family members. GSK-3b can inhibit
B-cell lymphoma 2 (Bcl-2) expression by phosphorylation of
CREB.42 GSK-3 can also regulate the myeloid cell leukemia
sequence 1 (Mcl-1) anti-apoptotic factor,43 although some recent
studies suggest that GSK-3 activity may not be necessary for Mcl-1
degradation.44 In addition, some studies have shown that GSK-3
stabilizes the expression of certain anti-apoptotic Bcl-2 family
members in leukemia cells.45
GSK-3b also has effects on the expression of the myeloblastosis
transcription factor (c-Myb) that is important in the regulation of
BCL2 transcription. Inhibition of GSK-3b repressed the expression
of c-Myb that, in conjunction with the lymphoid enhancer-binding
factor 1 (LEF-1) transcription factor, binds the promoter regions
of the BCL2 and BIRC5 (survivin) genes to prevent apoptosis of
leukemia cells.46
BIOCHEMICAL AND PHYSIOLOGICAL DIFFERENCES BETWEEN
GSK-3a AND GSK-3b
Although GSK-3a and GSK-3b are structurally similar, they are not
functionally identical. For example, GSK-3a cannot completely
compensate for GSK-3b as GSK-3b knockout (deletion of exon 2)
mice are embryonically lethal and die around embryonic day 16
because of liver degeneration caused by hepatocyte apoptosis.47
These studies also demonstrated that GSK-3b was essential for the
activation of NF-kB after tumor necrosis factor-a treatment in
hepatocytes. In contrast to GSK-3b knockout mice, GSK-3a
knockout mice animals were viable but displayed enhanced
glucose and insulin sensitivity and reduced fat mass. GSK-3a
knockout mice elicited metabolic and neuronal developmental
abnormalities.48,49 It has also been demonstrated that GSK-3a and
GSK-3b have different substrate preferences in the brain.50 In
summary, GSK-3 isoforms exhibit tissue-speciﬁc physiologically
important functions that are sometimes different. Thus, there are
rationales for the speciﬁc targeting of GSK-3a or GSK-3b in certain
diseases.
Most studies have focused on GSK-3b; however, some studies
have demonstrated roles for GSK-3a in drug resistance and cancer
stem cells. GSK-3a has also been identiﬁed as a key target in other
cancers including acute myeloid leukemia (AML).51
INTERACTIONS BETWEEN GSK-3 AND PI3K/PTEN/AKT/MTORC1
PATHWAY
GSK-3 is a critical enzyme that is often associated with the
phosphoinositide 3-kinase (PI3K)/phosphatase and tensin
homolog (PTEN)/Akt/mammalian target of rapamycin complex
1 (mTORC1) and Wnt/b-catenin pathways that are often deregu-
lated in leukemia and myeloma.52–68 GSK-3 has complex
interactions with these pathways. Some of the interactions of
GSK-3 and the PI3K/PTEN/Akt/mTORC1 and Ras/Raf/MEK/ERK
pathways are presented in Figure 1. GSK-3b can be negatively
regulated through phosphorylation on S9 by active Akt. When
GSK-3b is phosphorylated by Akt, GSK-3b is inactive.
TSC1/TSC2 REGULATION OF MTORC1
Akt-mediated regulation of mTORC1 activity is a complex,
multistep phenomenon. Akt inhibits tuberous sclerosis complex
2 (TSC2; tuberin) function through direct phosphorylation.64 TSC2
is a GTPase-activating protein (GAP) that functions in association
with tuberous sclerosis complex 1 (TSC1; hamartin) to inactivate
the small G-protein Rheb (Ras homolog enriched in brain).64 TSC2
phosphorylation by Akt represses GAP activity of the TSC1/TSC2
complex, allowing Rheb to accumulate in a guanosine-
5’-triphosphate (GTP)-bound state. Rheb-GTP then activates,
through a mechanism not yet fully elucidated, the protein
kinase activity of mTOR present in the mTORC1 complex.
Clearly, regulation of these complexes play critical important
roles in cell proliferation and leukemia. These are sites of
intervention in many antileukemia and anticancer therapies.52–64
TSC1/TSC2 can regulate mTORC1 activity and GSK-3 can play
a key role in this regulatory circuit. The TSC1/TSC2 complex can
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negatively regulate proliferation through mTORC1 inhibition and
GSK-3b activation. GSK-3 can also interact with TSC1/TSC2 by
phosphorylating TSC2 and activating it.64
GSK-3 can phosphorylate p70S6K.34 This is another point where
GSK-3 interacts with the PI3K/Akt/mTOR pathway. GSK-3 can
phosphorylate S371 on p70S6K and regulate its activity. mTORC1
cooperates with GSK-3 to regulate p70S6K activity and cell
proliferation.34 GSK-3 can phosphorylate TSC2 that results in
inhibition of mTORC1 and subsequent phosphorylation of p70S6K
at T389.66
OVERVIEW OF WNT/b-CATENIN SIGNALING AND CRITICAL
INVOLVEMENT OF GSK-3
There are basically two Wnt signaling pathways: one is referred to
as canonical Wnt signaling, which is b-catenin dependent,
whereas the other signaling pathway is referred to as noncano-
nical Wnt signaling, which is b-catenin independent. b-Catenin
can play various roles in cell physiology. Different pools of
b-catenin have been proposed to be present at different locations
in the cell. One pool of b-catenin is associated with cadherins at
the cell–cell junctions. Another pool of b-catenin is ‘free’ and
Figure 1. Interactions of the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways with GSK-3. Some of the regulatory interactions
between GSK-3 and Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways are indicated. An activated growth factor receptor is indicated
in blue. Ras and Rheb are indicated in dark blue ovals. IRS1 is indicated in an orange oval. Kinases are indicated in green ovals with the
exception of GSK-3b, which is indicated in a red oval. The p85 regulatory subunit of PI3K is indicated in a green oval. The phosphatases that
inhibit steps in this pathway are indicated in black octagons. The phosphatases PP2A and PP1 that may activate GSK-3 are indicated in yellow
octagons. NF1, TSC1 and TSC2 are indicated in black squares. PIP2 and PIP3 are indicated in yellow ovals. Phosphatases are indicated in black
octagons. mTOR interacting proteins that positively regulate mTOR activity are indicated in yellow ovals. mTOR interacting proteins that
negatively regulate mTOR activity are indicated in black ovals. Transcription factors activated by either ERK or Akt phosphorylation are
indicated in yellow diamonds. The FOXO transcription factor that is inactivated by Akt phosphorylation is indicated by a black diamond.
b-Catenin is indicated in an orange oval. mRNA initiation factors and proteins associated with the ribosome are indicated in magenta ovals.
mTORC1 phosphorylates the ULK1 (unc-51-like kinase 1) that results in the suppression of autophagy. ULK1 is indicated in a black oval.
Proteins involved in the regulation of translation are indicated in purple ovals. Red arrows indicate activating events in pathways. Black arrows
indicate inactivating events in pathways. Activating phosphorylation events are depicted in red circles with Ps with a black outlined circle.
Inactivating phosphorylation events are depicted in black circles with Ps with a red outlined circle. This figure is provided to give the reader an
idea of the complex interactions of GSK-3 with various signaling molecules in the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways
that are key in regulating cellular proliferation survival and often become dysregulated in cancer.
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present in the cytosol and nucleus where it plays important roles
in regulating gene expression. Normally, this pool of ‘free’
b-catenin is maintained at a low level by rapid turnover. GSK-3
is important in regulating the turnover of b-catenin. An overview
of the Wnt/b-catenin pathway is presented in Figure 2.
The Wnt gene family consists of B19 genes in mammals. Wnt
genes are present in multicellular animals but not in single-cell
organisms, suggesting a key role for the Wnt genes in the
evolution of multicellular organisms.67,68 Signaling induced by
heterodimeric Wnt receptors results in a ligand-induced
conformation change of the receptors, resulting in the
phosphorylation of target proteins. Wnt binds a member of the
Frizzled (Fz) family members (N¼ 10), the membrane-bound
receptors that are G protein-coupled receptors. A co-receptor for
Wnt is the transmembrane protein called low-density lipoprotein
receptor-related proteins 5/6 (LRP5 or LRP6). In addition, there are
other receptor tyrosine kinases such as the receptor-tyrosine-
kinase-like orphan receptor 1 (ROR1) and ROR2 as well as the
receptor tyrosine kinase-like proteins that can interact with
Wnt.52,68
BIOCHEMICAL REGULATION OF b-CATENIN BY GSK-3
In unstimulated cells, CK1 phosphorylates b-catenin at S45 that
primes b-catenin for subsequent phosphorylation by GSK-3
at S41, S37 and S33.24,67,68 Thus, b-catenin is targeted for
ubiquitination and proteasomal degradation.24 An enlarged view
Figure 2. Overview of Wnt/b-catenin induced gene expression. In the presence of Wnt, b-catenin is stabilized and can induce gene
transcription. Wnt binds its coreceptors Fz and LRP5/LRP6. The Fz transmembrane receptor is indicated by a squiggly line to indicate its
spanning the membrane seven times. The LRP5 and LRP6 transmembrane receptors are indicated by a red oval. Various molecules that
interact with the receptors and GSK-3 and CK1 are indicated in yellow ovals. Various Wnt inhibitors such as WIF, DKK and sFRP are presented
as red octagons. When Wnt is present, b-catenin is stabilized and able to induce gene expression by complexing with various transcription
factors including TCF/LEF, TBX5 and HIF-1a that are indicated by yellow diamonds. Various proteins that interact with the transcription factor
complexes are indicated in pink circles. Kinases that can regulate these molecules are indicated by green ovals. The Rac-1 exchange factor is
indicated in a purple circle. This figure is presented to provide the reader an idea of how activation of Wnt/b-catenin can result in regulation of
gene expression.
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of the Wnt/b-catenin and b-catenin destruction complex is
presented in Figure 3.
If the Wnt ligand is present, it binds its receptor Fz, which
signals through Dvl to suppress b-catenin phosphorylation, and
b-catenin is able to complex with LEF/T-cell factor (TCF) and
induce the transcription of genes. When mutated, b-catenin acts
as an oncogene, as in some cases it cannot be phosphorylated by
GSK-3 and CKI. Other regulatory proteins are also involved.
Some of them are oncogenes/tumor-suppressor genes. The
GSK-3-binding protein (GBP, also known as FRAT (frequently
Figure 3. Comparison of Wnt activation of b-catenin signaling vs formation of b-catenin destruction complex. (Left panel) In the presence of
Wnt, b-catenin is stabilized and can induce gene transcription. Various proteins that interact with the transcription factor complexes are
indicated in pink circles. The Rac-1 exchange factor is indicated in a purple circle. When Wnt is absent, b-catenin is targeted for proteasomal
degradation. GMP, indicated in a yellow oval, is displaced from GSK-3 and GSK-3 is able to phosphorylate b-catenin that results in its
ubiquitination by the b-TrCP complex, indicated in a yellow oval. Ubiquitination is indicated by Ub in purple circles. Axin is also poly-ADP-
ribosylated TNKS that is linked by PAR indicated by a purple circle that subsequently leads to its proteasomal degradation. TCF/LEF interacts
with various proteins including the transcriptional regulators histone deacetylases (HDACs) and Grg/TLE, indicated in black ovals, that prevent
it from inducing gene transcription. This figure is presented to provide the reader an idea of how b-catenin turnover can be regulated by
GSK-3 and CK1 phosphorylation.
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rearranged in advanced T cell)) may regulate the binding of GSK-3
to Axin. Diversin (Div) is an ankyrin-rich protein and can interact
with both Dvl and Axin to facilitate Wnt signaling. The b-catenin
destruction complex consists of GSK-3, b-catenin, Axin/conductin
and adenomatous polyposis coli (APC). APC is a tumor-suppressor
gene. APC is an essential component of the b-catenin complex
that controls cytoplasmic b-catenin levels. Mutations at APC
result in elevated levels of b-catenin and lead to the expression of
Wnt/b-catenin-responsive genes. The Axin and related conductin
(Axil) proteins contain multiple protein–protein interaction
domains and together with APC form key components of the
b-catenin destruction complex. GSK-3 phosphorylates both Axin
and APC. GSK-3 phosphorylation of Axin increases it stability as
well as its binding to b-catenin.69 CKI acts as a priming kinase by
phosphorylating Axin, Dvl and APC. GSK-3 then phosphorylates
these proteins. The Div protein recruits CKI to the b-catenin
destruction complex.70
GBP plays key regulatory roles in the interactions that GSK-3 has
with other proteins. The binding sites for Axin and GBP on GSK-3
overlap. If GSK-3 is bound to GBP, GSK-3 cannot bind Axin and
GSK-3 does not phosphorylate b-catenin.71 GBP also regulates the
nuclear export of GSK-372 and may control the accessibility of
nuclear and cytoplasmic substrates to GSK-3.
Dvl binds the cytoplasmic portion of Fz. Wnt/Fz then becomes
associated with LRP5 or LRP6, which are co-receptors for Wnt.
Casein kinase 1d (CKId) phosphorylates LRP6 on T1479. GSK-3b
can then play a positive role in Wnt signaling by phosphorylating
LRP6 on S1490. These phosphorylation events are necessary for
Axin to bind to the complex and b-catenin stabilization. The
stabilized b-catenin can then enter the nucleus and have effects
on gene transcription.73 A diagram of the positive effects that CKI
and GSK-3 exert on Wnt/b-catenin signaling is present in Figure 4.
This ﬁgure also illuminates why GSK-3 inhibitors may be effective
in targeting certain leukemias.
Axin binds to the cytoplasmic portion of LRP6. This complex
may then recruit b-catenin from the b-catenin destruction
complex and inhibit the ability of GSK-3 to phosphorylate
b-catenin (CTNNB1). When Wnt signaling is active, GSK-3-mediated
phosphorylation of S33, S37 and T41 on b-catenin is suppressed.
In contrast, there is no effect on CK1a-mediated phosphorylation
of S45.
Thus, there are two roles for GSK-3 in the regulation of Wnt/b-
catenin signaling: phosphorylation of LRP5/6, which stabilizes
Axin, and phosphorylation of b-catenin, which targets it for
proteasomal degradation. There may be different pools of GSK-3
in cells: one linked with Axin that is resistant to phosphorylation
by Akt and another pool that is regulated by Akt.74 Ectopic
expression of activated Akt did not appear to activate b-catenin
signaling in the cells examined as measured by changes in
the levels of accumulation of cytosolic b-catenin activation of
LEF1-dependent transcription.74 Wnt may induce the translocation
of GSK-3 and Axin to the plasma membrane that is dependent
Figure 4. Positive effects of GSK-3 on Wnt/b-catenin signaling. This figure is presented to emphasize the point that GSK-3 and CK-1 can
phosphorylate and stabilize LRP5/6 that promotes b-catenin signaling. This is a site where GSK-3 inhibitors would inhibit b-catenin-mediated
gene expression.
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upon interactions with Fz and Dvl.75 The presence of Axin is
required for GSK-3 to phosphorylate LRP5/6. CKIg is also
associated with LRP5/6 upon Wnt signaling and may also be
involved in the Wnt-induced Axin recruitment.76
When Wnt signaling is turned off, CKIa phosphorylates
b-catenin on S45. Then, GSK-3b phosphorylates b-catenin on
S33, S37 and T41.67,68 The Axin/GSK-3/CK1/APC complex normally
promotes the degradation of the b-catenin via ubiquitylation by
the SKP1/cullin1-F-box E3 ligase (b-TrCP) complex in the 26S
proteasome. APC interacts with both GSK-3 and b-catenin. Axin
functions as the scaffold of the destruction complex. APC directly
binds Axin. Axin is phosphorylated by GSK-3 and CKIa. The normal
afﬁnity of b-TrCP for b-catenin is low. Wilms tumor suppressor
(WTX) is a protein that can increase the afﬁnity of b-TrCP for
b-catenin.77 WTX forms a complex with b-TrCP, b-catenin, Axin
and APC. This complex promotes b-catenin ubiquitylation and
subsequent proteasomal degradation.
Axin, APC and WTX are considered tumor-suppressor proteins.
WTX is also present in the b-catenin destruction complex and
promotes b-catenin degradation. APC has recently been shown to
increase the activity of GSK-3.78 GSK-3 and CKIa phosphorylate a
serine in the PPPSP motif found in many Wnt signaling
components such as b-catenin, Axin and APC.
WNT/b-CATENIN-INDUCED TRANSCRIPTIONAL EFFECTS
Wnts induce rapid APC dissociation from Axin that leads to
b-catenin stabilization. In the absence of Wnt activation, the
transducin-like element (TLE, also known as Groucho, Grg) is
bound to TCF and forms a transcriptional repressive complex that
recruits histone deacetylases to repress Wnt target gene
transcription. In the presence of binding of certain Wnts to Fz
and LRP5 or LRP6, a signal is transmitted across the membrane
and Dvl is activated. Activated Dvl then inhibits the b-catenin
destruction complex. b-Catenin is not phosphorylated, it can
translocate to the nucleus, replace TLE and bind transcription
factor TCF/LEF and recruit numerous transcriptional co-activators
and histone modiﬁers such as Brg-1, CBP, Cdc47, Bcl-9, Pygopus
and histone acetyltransferases and induce the transcription of
many genes associated with proliferation including cyclin D1,
c-Myc, c-Jun, Yes-associated protein and vascular endothelial
growth factor.67,68 One target of Wnt/b-catenin/TCF is the
Axin2 gene and is considered a general indicator of Wnt
pathway activation.79 DKK1 is actually a downstream target of
Wnt/b-catenin pathway.80
DIVERSE EFFECTS OF DIFFERENT WNTS
Different Wnt family member proteins have various biological
effects that may also be tissue speciﬁc. Wnt3A and Wnt7A
promote the growth of certain cancers, but not others. For
example, Wnt7A promotes b-catenin-dependent transcription in
ovarian cancer cells.81 In contrast, it inhibits the growth of certain
leukemias, potentially by a b-catenin-independent mechanism.82
The different effects of Wnt-7 on various types of cells have been
postulated to result from the presence of diverse receptors
expressed on the particular cell types.68 Certain Wnts will
induce genes associated with differentiation and suppression
of proliferation in one cell type, yet in other cell types induce the
expression of genes associated with growth and survival.
b-CATENIN-INDEPENDENT SIGNALING PATHWAYS
In noncanonical Wnt signaling pathways, b-catenin is not
engaged; however, some of the components of the canonical
Wnt signaling pathway may be involved. In some cases, Wnt5A
and Wnt1 do not stabilize b-catenin but they regulate pathways
associated with cell migration and mobility.68 In some cases, Fz
and Dvl are involved. In other cases, Wnt interacts with receptor
tyrosine kinases located at the cell membrane such as RYK and
ROR2 that transduce their signals further to Src and Jun N-terminal
kinase (JNK), respectively. Wnt can also interact with Fz and
Dvl and affect CDC42 and Rac activity. Alternatively, DVL can
interact with Disheveled-associated activator of morphogenesis
1 (DAAM1), Ras homolog gene family member A (RhoA) and JNK.
Activation of these pathways is often associated with events at the
cytoskeleton. JNK activity will also affect the expression of certain
genes such as Ap-1 and nuclear factor-activated T cell (NF-AT).
Wnt can also interact with Fz and Dvl and further associate with
phospholipase C that results in mobilization of intracellular
Ca2þ and activates protein kinase C and Ca2þ /calmodulin-
dependent protein kinase (CaMKII), leading to activation of
NF-AT in the nucleus. There are also other pathways with which
Wnts can interact, such as the planar cell polarity signaling
pathway, and these pathways have been discussed in a recent
comprehensive review on Wnt signaling in cancer.68 Wnt5a
can inhibit proliferation and induce cellular senescence or have
tumor-suppressor effects in certain cancer types as it can
antagonize b-catenin-dependent transcription.83,84 Inactivation
of Wnt5a expression in certain mouse models resulted in
the development of B-cell lymphomas and chronic myeloid
leukemias (CMLs), indicating that Wnt-5 has important tumor-
suppressor activity in certain hematopoietic lineages, at least
in mice.85 However, in other cancer types, Wnt-5 can enhance
tumor growth.
WNT RECEPTORS OVEREXPRESSED IN CANCERS
Various Fz receptors have been implicated in cancer. Fz6
was determined to be overexpressed in the T-cell lymphoma
breakpoint 1 (Tcl1þ / , Emu-TCL1) mouse model that
develops chronic lymphocytic leukemias (CLLs) spontaneously.
The investigators demonstrated that during the course of
leukemogenesis, expressions of Wnt16, Wnt10a, Fz1 and Fz6
were elevated in the transformed CD5(þ ) B cells along with
b-catenin protein levels. Creation of Tcl1þ / , Fzd6 / double
mutant mice resulted in suppression of development of the
leukemia and lymphomas. In contrast, deletion of Fz9 had no
effects on cancer development in this Tcl1þ / model.86
ROLES OF WNT/b-CATENIN AND LEUKEMIA-INITIATING/STEM
CELLS
The earliest description of the involvement of the Wnt/b-catenin
pathway in cancer stem cells was probably in leukemia-initiating
cells (LICs)/leukemia stem cells (LSCs). Certain LSCs have been
demonstrated to have higher levels of b-catenin that was also
driving their establishment and drug resistance.87,88 Other
components of the Wnt/b-catenin signaling pathway may be
differentially expressed in certain LICs/LSCs, these include loss of
functional APC, decreased expression of secreted frizzled-related
protein (sFRP1), DKK1, increased expression of TCF7l2, Bcl-9, Fzd6,
Wnt5A and Wnt7. Wnt/b-catenin signaling was determined to be
required for self-renewal of not only normal hematopoietic stem
cells (HSC) but also LSCs.
WNT SIGNALING IN STEM CELL SELF-RENEWAL
Stem cells have the capacity to self-renew as well as produce
specialized cells. The choice to self-renew or produce specialized
cells may be dictated by extrinsic signaling factors that are present
in the niche or in an area that functions as a signaling center.
Many of these factors act within the near vicinity of the stem cells
in order to tightly regulate them. Key pathways involved in
regulating the niche are: Wnt, BMP, Hh and Notch.67,89,90 Altering
the activity of the Wnt pathway has been shown to affect HSCs.
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Overexpression of Axin decreased the number of transplantable
HSCs.91 Treatment of HSCs with the Wnt-3a protein increased
self-renewal and long-term reconstitution in irradiated mice.89
Wnt proteins have also been shown to promote maintenance of
pluripotency in murine embryonic stem cells (ESCs).92 The
mechanisms by which Wnt signals maintain stemness are not
fully elucidated. Clevers and Nusse67 have suggested that stem
cells are intrinsically destined to differentiate and that Wnt signals
could block the differentiation step by suppressing differentiation-
speciﬁc genes as Wnt signals can also suppress the expression of
certain genes.
GSK-3 INVOLVEMENT IN HSC HOMEOSTASIS
Normal HSCs exit quiescence under the appropriate circumstances
to either maintain a balanced number of self-renewing cells or
generate the required lineage-differentiated progeny cells neces-
sary to fulﬁll the loss of mature blood cells. GSK-3 exerts important
regulator functions on the quiescent HSC pool. GSK-3 plays key
roles in HSC homeostasis.93 By using a loss of function approach,
the authors demonstrated a key role of GSK-3 in controlling HSC
homeostasis. Loss of functional GSK-3 activity in the bone marrow
(BM) transiently expanded HSCs in a b-catenin-dependent fashion,
documenting a role for Wnt/b-catenin signaling in homeostasis.
Loss of GSK-3 activity in the HSC led to their depletion by
activation of mTORC1. Depletion of the HSCs in the GSK-3-
deﬁcient BM was prevented by treatment with mTORC1 inhibitors.
Thus, GSK-3 is a master switch that regulated both Wnt/b-catenin
and mTORC1 signaling that, in turn, controls HSC self-renewal and
lineage commitment, respectively. The authors of this important
study have suggested a potential therapeutic approach to expand
HSCs in vivo using drugs already approved for treatment of other
diseases (lithium to inhibit GSK-3 and rapamycin to inhibit
mTORC1).
GSK-3 antagonizes mTORC1 activity by phosphorylating TSC2
that in turn inhibits Rheb and mTORC1 activity. PTEN is upstream
of GSK-3. PTEN negatively regulates Akt activity. Akt negatively
regulates GSK-3 activity. Interestingly, PTEN and TSC1 knockout
mice have similar hematopoietic phenotypes as increases in HSCs
were transiently observed that was then followed by HSC
depletion and lineage commitment.94,95 There are, in addition,
other tumor suppressors that were induced in PTEN-mutant mice
indicating the complex interacting genetic factors between PTEN
loss and mTOR activation.96 Interesting, knockdown of GSK-3a and
GSK-3b induced a similar HSC phenotype as observed in PTEN /
and TSC-1 / mice as the HSCs initially increased and then they
were progressively depleted.97 These studies indicated that GSK-3
plays critical roles in the HSC homeostasis and controlling the
decision between self-renewal and differentiation. These
pathways have opposing functions in HSC self-renewal and
differentiation. Moreover, Wnt signaling induced mTORC1
activity by inhibiting the negative effects that GSK-3 had on
mTORC activity. These results suggested a division of the
canonical Wnt pathway with Wnt or GSK-3 inducing opposing
signal pathways, each of which can activate potentially opposing
processes (HSC renewal vs differentiation). Likely, there will be
other factors and molecules discovered that can shift the balance
and modify HSC homeostasis.
HSCs reside in the BM in a reduced-nutrient and low-oxygen
tension niche. Moreover, nutrient-sensing pathways interact
to regulate HSC homeostasis. The mTORC1 and LKB1 pathways
are key nutrient-sensing pathways and dysregulation of these
pathways alters HSC homeostasis. Decreased LKB1 activity98
or increased mTORC1 activity96 will induce the proliferation of
committed progenitors and decrease HSCs. These studies have
indicated that low-nutrient availability is a critical component that
regulates HSC homeostasis.
Subsequently, studies by the Klein group98 demonstrated that
suppression of this pathway by rapamycin combined with
activation of Wnt/b-catenin pathway by GSK-3 inhibitors
permitted ex vivo maintenance of human and mouse HSCs in
the absence of exogenous cytokines. These observations further
the previous studies of the authors and demonstrated that two
drugs (the mTOR inhibitor rapamycin and the GSK inhibitor
CHIR99021) increased the number of long-term HSCs in vivo.99
These studies document the essential regulatory roles of GSK-3 in
HSC homeostasis as a suppressor of Wnt/b-catenin self-renewal
pathway and also as a suppressor of the mTORC1 pathway that
would normally promote lineage commitment and stem cell
depletion. Inhibition of GSK-3 with lithium activated self–renewal,
whereas suppression of mTORC1 with rapamycin prevented HSC
depletion, allowing the generation of long-term HSCs (but not the
proportion) in vivo. Thus, the approach described by Klein et al.98
may also prove useful for both hematopoietic recovery and
immune reconstitution in umbilical cord blood transplantation.
The studies by Ito et al.100,101 have identiﬁed a metabolic
requirement of promyelocytic leukemia (PML)–peroxisome
proliferator-activated receptor-d (PPARd)–fatty-acid oxidation
(FAO) pathway. PPARd signaling and FAO is important for
maintaining the equilibrium between HSC maintenance and
function. The PPAR–FAO pathway is downstream of PML
and can be viewed as a critical regulatory switch that is essential
for HSC maintenance and control of asymmetric cell division.
Both the PPARd pathway and FAO can be pharmacologically
manipulated and therefore are relevant to stem cell and cancer
therapy. Furthermore, PML can be targeted with arsenic trioxide.
Inhibition of GSK-3 allowed mouse ESCs to maintain pluripo-
tency.102 ESCs lacking GSK-3a and GSK-3b maintained some
markers of pluripotency even when cultured under conditions that
induced differentiation.103
GSK-3 AND LEUKEMIA
Over the past few years, GSK-3 has been documented to play
pivotal roles in various leukemias and may therefore be a key
therapeutic target. As stated previously, GSK-3 has an important
role in regulating b-catenin levels. However, b-catenin is largely
dispensable for the function of normal HSCs.104 In contrast,
b-catenin is often important and activated in leukemia and is
often associated with drug resistance and LSCs.87 Dysregulation of
Wnt/b-catenin has been observed in AML and was associated with
a poor prognosis.105 Furthermore, the chemoresistance of certain
AML cells was shown to be dependent on the Wnt/b-catenin
pathway and integrins. This chemoresistance required functional
GSK-3 activity that mediated its effects via NF-kB. Thus, GSK-3 is a
target for certain AMLs. Note that this is an example of where
GSK-3 is functioning as a tumor promoter.
Recently, it has been demonstrated by genetic and chemical
genomic screens that GSK-3a is a target for AML.51 The authors
identiﬁed GSK-3a as a target by performing two independent
small-molecule library screens and a small hairpin RNA (shRNA)
screen for changes in gene expression that induced a
differentiation signature in two AML cell lines: HL-60 and U937.
Loss of GSK-3a activity induced differentiation in AML cells as
measured by many parameters including morphological changes,
cell surface marker expression and gene expression signatures, all
being consistent with myeloid differentiation. GSK-3a inhibition
resulted in impaired growth and proliferation, induction of
apoptosis, loss of colony-forming ability in methylcellulose
in vitro and inhibition of AML proliferation in vivo. GSK-3a
inhibition was anti-correlated with gene sets obtained by
coexpression of HOXA9 and MEIS1 in hematopoietic cells.
Furthermore, c-Myc expression and c-Myc-regulated genes were
also downregulated upon GSK-3a inhibition, which may be
a mechanism of AML differentiation.
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The effects of inhibition of GSK-3 by lithium treatment has been
examined in clinical trial with AML patients treated with cytosine
arabinoside and daunorubicin.106 This clinical study demonstrated
that the percentage of AML patients with complete remission was
signiﬁcantly lower in those patients who received lithium (75% vs
49%). These results suggest that more potent GSK-3 inhibitors
might have greater anticancer effects, at least with some cancers.
However, there remains concern that inhibiting GSK-3 may
promote the growth of certain cancer types.
Another mechanism by which GSK-3 may impair differentiation
in AML is its interaction with the retinoic acid receptor (RAR).107
RAR is impaired by rearrangement in the acute promyelocytic
leukemia (APL) subtype (acute PML), which is characterized by the
translocation t(15;17), RARA-PML. APL can be differentiated and
cured by the RAR ligand all-trans retinoic acid. GSK-3 can
phosphorylate and inactivate RAR, and GSK-3 inhibition
enhances the differentiation potential of all-trans retinoic acid
even in non-APL AML.
Recently, it has been demonstrated that there are complex
interactions between Akt and FOXO3 levels in maintaining LICs.62
Low levels of Akt were associated with elevated levels of Forkhead
box O3 (FOXO3) that were required to maintain the functionality
and immature status of the LICs. Decreased levels of FOXO3
promoted differentiation, maturation and apoptosis of the
MLL-AF9 LICs and improved animal survival. Decreased levels of
FOXO were associated with increased levels of JNK/c-Jun
activation in the resistant leukemia cells that persisted despite
reduced levels of FOXO. JNK inhibitors could potentiate the effects
of Akt activation or FOXO3 depletion and induce differentiation
of the AML LICs. The authors have suggested that mTORC1 and
GSK-3b may provide important signals between Akt and FOXOs
that abrogated the effects of FOXO suppression.62
TARGETING b-CATENIN IN CML
Recently, it was shown that Wnt/b-catenin signaling is necessary
for CML LSC survival. b-Catenin inactivation has been demon-
strated to target imatinib-resistant CML LSCs.108 Studies with
b-catenin conditional knockout mice have determined that
although b-catenin was required for the self-renewal properties
of fetal HSCs, it was not required for the maintenance and
self-renewal of adult HSCs.
Importantly, Heidel et al.108 demonstrated that the nonsteroidal
anti-inﬂammatory drug indomethacin targets b-catenin and can be
used to inhibit CML LSCs. b-Catenin inhibition may represent
a novel approach to treat minimal residual disease that is due to the
presence of imatinib-resistant CML LSCs. b-Catenin signaling is
necessary for CML LSC maintenance but it is not required for the
survival of the bulk population of CMLs (non-LSCs). Inactivation of
the b-catenin gene (CTNNB1) was shown to hinder the development
of CML.109 In the studies by Heidel et al.108 using a conditional
b-catenin knockout mouse and BCR-ABL-infected BM cells, the
combination of b-catenin loss and imatinib treatment reduced the
serial transplantability of CML LSCs at least 100-fold. Although
inhibition of Wnt/b-catenin signaling suppressed CML LSC survival, it
did not affect the survival of the bulk CML cells. Thus, b-catenin-
mediated downstream gene expression was necessary for the
maintenance of the critical stemness/self-renewal properties of CML
LSCs. Furthermore, the authors demonstrated that treatment with
indomethacin potentiated the effects of imatinib as mice treated
with both drugs had lower numbers of CML LSCs. In primary CML
patient samples, reduced prostaglandin levels were associated with
an increased response to imatinib.
Differentiated CML cells are addicted to the BCR-ABL onco-
protein and hence they are normally sensitive to BCR-ABL inhibitors,
provided they do not have mutations in the rearranged BCR-ABL
gene that confers resistance to such inhibitors. These cells are often
referred to as the bulk leukemia cells. However, CML LSCs
proliferate slowly and often display altered drug pump expression
and resistance to BCR-ABL inhibitors. Thus, although whereas the
BCR-ABL inhibitors will suppress the bulk CML cells, they will not
eliminate the CML LSCs. Thus, the CML patient is dependent upon
continued treatment with BCR-ABL inhibitors and may develop
resistance to these inhibitors. Recently, a novel target (that is, the
SIRT1 (silent information regulator 1) gene) has been identiﬁed that
will synergize with BCR-ABL inhibitors to result in the suppression of
CML LSCs. SIRT1 is a member of the Sirtuin family of proteins that
are a unique class of histone deacetylase inhibitors as their
substrates can be either histones or nonhistone proteins. SIRT1 was
determined to be expressed at higher levels in the CD34þ
population of CMLs that was enriched in CML LSCs than in normal
CD34þ cells.110 Knockdown of SIRT1 expression in CD34þ CML
LSCs reduced their proliferation, increased apoptosis and decreased
their colony-forming ability. In contrast, knockdown of SIRT1 had
less effect on normal CD34þ cells. These results point to an
important role of SIRT1 in CD34þ cells. In addition, the authors
investigated the ability of the small-molecule p53 activator Tenovin
6 (TV-6) that inhibits the sirtuin family proteins to suppress CML
LSCs. TV-6 enhanced the ability of imatinib to reduce colony
formation and in vivo engraftment. SIRT1 will deacetylate p53 and
regulate its transcriptional activity.110 Inhibition of SIRT1 increased
p53 acetylation and transcriptional activity and increased the
effectiveness of the BCR-ABL inhibitor imatinib on the CML LSCs.
These effects would only be predicted to occur in patients with CML
LSCs containing wild-type TP53. This approach would not be
appropriate in CML patients with additional mutations at the BCR-
ABL gene that render them resistant to imatinib, or the B30% of
blast crisis patients who have inactivating mutations in TP53. An
overview of these events is presented in Figure 5.
Although not much is currently known about the interactions
between GSK-3 and SIRT1, there are some reports describing some
relationships between these protein families. SIRT1 can regulate
the Wnt pathway including b-catenin.111
Loss of b-catenin impaired the renewal of normal and CML stem
cells in mouse models.109 Interesting, in this study, loss of
b-catenin did not inhibit the progression of acute lymphocytic
leukemia in the CTNNB1-mutant mice.
Recently, it has been observed that the natural product
berbamine inhibits calcium calmodulin-dependent kinase IIg
(CaMKIIg) that is a critical regulator in CML LSCs.112 Berbamine
binds to the ATP-binding pocket of CaMKIIg and inhibits its
activity. Berbamine is an ATP-competitive inhibitor of CaMKIIg.
CaMKIIg was determined to be highly active in CML LSCs and
required for their proliferation and survival. In contrast, CaMKIIg
was not as highly activated in HSCs. CaMKIIg co-activated the
b-catenin and Stat3 signaling pathways. Berbamine inhibited the
growth of imatinib-resistant CML LSC cells as well as those con-
taining the T315I BCR-ABL mutation but not normal hematopoietic
cells. Berbamine inhibited NF-kB, b-catenin and Stat3 signaling.
ABERRANT GSK-3b MRNA SPLICING AND ITS EFFECTS ON
b-CATENIN IN CML
Aberrant GSK-3b mRNA splicing has been demonstrated to
increase in b-catenin expression in blast crisis (BC) CML LSCs. This
was reported to affect the replating ability of the CML LSCs.113
Previously, the authors had observed that higher levels of nuclear-
localized b-catenin were expressed in BC CML LSCs than in the
granulocyte macrophage progenitor (GMP) pool from normal
BM.88 In this subsequent study, the complementary DNA
sequences of a number of genes in the Wnt/b-catenin pathway
were examined, including APC, GSK3B, AXIN1, CTNNB1, LEF1,
CCND1 and MYC. The authors examined the complementary
DNA sequences of these genes in 15 normal, 4 chronic-phase, 1
accelerated-phase and 8 myeloid BC CML samples. Novel in-frame
splice deletions were detected in BC CML GMPs that are enriched
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with LSCs. Aberrant GSK-3b splicing events were detected in four
out of seven patient samples that resulted in deletions of exons 8
and 9. Exons 8 and 9 encode the FRAT (also known as GBP) and
Axin binding domains, and their deletion resulted in the inability
of GSK-3b to bind Axin and induce the phosphorylation and
inactivation of b-catenin. Other in-frame splice domain mutations
that resulted in loss of either exon 9 or 11 or exon 9 and 11 were
detected in CML blasts as well as chronic-phase CML and normal
peripheral blood, BM and cord blood, but in-frame splicing
mutations resulting in deletion of exons 8 and 9 were not
detected in these cell fractions. The GMP BC CMC cells with
mutant GSK-3b had elevated levels of b-catenin and displayed
increased serial engraftment capabilities. Introduction of a full-
length GSK-3b complementary DNA into the GMP BC CMC cells
with the mutant GSK-3b splicing mutations reduced in vitro
replating as well as leukemia engraftment.
GSK-3 REGULATION OF RNA BINDING PROTEINS IMPLICATED
IN CML LSCS
Another target in CML LSCs is the RNA-binding protein Musashi2
that represses Numb. The Numb protein functions in cell fate by
regulating asymmetric cell division, through degradation of Notch.
Musashi1 and Musashi2 are highly related proteins and display
490% identity at the amino sequence level in their RNA
recognition motifs. Musashi2 is ubiquitously expressed, whereas
Musashi1 displays a more limited expression pattern and is
reported to be expressed in embryonic and adult neural stem
cells.114 Musashi2 is expressed at higher levels in hematopoietic
cells than Musashi1. Musashi2 expression was elevated in
stem cells and was detected at 10-fold higher levels in
immature BC CML. Musashi2 was most enriched in the lineage-
negative fraction of BC CML. Musashi2 is thought to be a putative
marker of cancer-initiating cells and its expression was higher in
Figure 5. Novel approaches of targeting signaling pathways in leukemia. (a) Effects of indomethacin on CML-LSC. b-Catenin is essential in
CMC LSCs that are resistant to imatinib, and treatment with indomethacin inhibits b-catenin and sensitizes the CML LSCs to imatinib. In
contrast, in bulk CML b-catenin in not essential and cells are addicted to BCR-ABL and sensitive to BCR-ABL inhibitor imatinib. (b) Recently, it
has been discovered that the activity of SIRT1, a NAD-dependent deacetylase, is increased in CML LSCs that are resistant to imatinib, whereas
decreased levels are detected in bulk CMCs that are sensitive to imatinib. Also it has been shown that upon treatment of CML-LSC with
Tenovin-6, a small-molecule activator of p53, p53 was acetylated and there was increased p53 activity and the CML LSCs became sensitive to
imatinib. (c) The CaMKII pathway has been shown to be important in the regulation of b-catenin in imatinib-resistant CML LSCs. Treatment of
CML LSCs with the natural product berbamine resulted in CaMKII and b-catenin inhibition and death of the CML LSCs. (d) Berbamine is also
effective in inhibiting the growth of bulk CMLs containing the T315I-BCR-ABL mutation in part by inhibiting CaMKII, NF-kB, b-catenin and STAT
signaling pathways. (e) The combination of BCR-ABL and GSK-3 inhibitors has been shown to induce a pro-differentiation/apoptotic pathway
in CML LSCs. (f ) Indomethacin is also effective in inhibiting AML LICs and AML LSCs that are c-Kit high and dependent on b-catenin signaling.
This figure is included to provide the reader some of the novel approaches to successfully target CML LSCs and AML LICs and the importance
of b-catenin in the survival of both CML LSCs and AML LICs.
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cells with high levels of total Wnt/b-catenin signaling.115
An overview of the effects of Musashi2 on BC CML and the
interactions with Numb and other signaling pathways is presented
in Figure 6.
The Numb protein plays key roles in the determination of cell
fate during development. Numb inﬂuences cell-fate decisions by
suppressing the effects of Notch. Numb was originally identiﬁed
as a cell-fate determinant in Drosophila development. The name
Numb arose as loss of Numb activity in Drosophila resulted in a
deﬁciency of sensory neurons; hence, the ﬂies were ‘Numb’. Numb
has important roles in maintenance of the normal stem cell
compartment. It can regulate the Notch, p53, Hh and other
pathways and is considered a tumor-suppressor gene. It is
involved in asymmetric cell division. Musashi represses Numb by
binding the 30 untranslated region of the Numb mRNA. In the
chronic phase of CML, high levels of Numb were detected,
whereas in the BC stage, lower levels of Numb were observed.116
In addition, the Reya group116 observed that ectopic expression of
Numb promoted differentiation of CML and impaired advanced-
phase CML. Furthermore, they demonstrated that an oncogene
associated with the blast phase of CML, NUP98-HOXA9, triggered
the expression of Musashi2, which in turn repressed Numb.
Musashi2 expression was determined to be upregulated during
human CML progression and was also an early indicator of
a poorer prognosis. Decreased Numb expression in BC-phase CML
suggests that low levels of Numb may be essential for maintaining
the CML cells at an immature stem-like phenotype. These studies
suggest that a potential therapy of CML-LSC cells could be to
increase Numb levels in cells that would trigger differentiation and
then treatment with imatinib to inhibit disease progression.
Numb can antagonize Notch signaling. GSK-3b can also inhibit
Notch signaling.117 Notch signaling is elevated in BC CML.116
Numb expression can reduce the incidence and propagation of BC
CML. p53 is a target of Numb. p53 levels were higher in
Numb-expressing BC CML and the inhibitory effects of Numb
were dependent on functional p53 activity. NUP98-HOXA9 induced
the expression of Musashi2 that resulted in decreased Numb
expression that contributed to BC CML. Genetic studies have
indicated that loss of Musashi2 expression impaired leukemia in
genetically mutated (gene trap) mice lacking the Musashi2 gene.
The effects of shRNA knockdown of Musashi2 were also
determined. Transfection of established BC CML with shMusahi2
increased the expression of Numb and reduced leukemic growth
in vitro and also resulted in more differentiated CML cells that
displayed decreased ability to propagate the disease. The authors
concluded that Musashi2 is important for the establishment and
propagation of BC CML.116
The authors of this important study examined the expression of
Musashi2 in CML patients. Musashi2 was determined to be
expressed at higher levels in BC CML patients whereas Numb was
downregulated. As many BC CML patients contain mutations at
other genes, the authors also examined the expression of HOXA9
in CML patients. HOXA9 expression was also elevated in BC
patients that may result in the increased expression of Musashi2.
HES1 and TRIP, which are targets of Notch signaling, were also
upregulated in the BC CML patients. The authors determined that
increased Musashi2 expression was associated with a higher risk
of relapse and a higher risk of death. Thus, Musashi2 expression
may be an early marker of advanced CML disease. Although
BCR-ABL did not appear to affect the decision of asymmetric or
symmetric division, NUP98-HOXA9 promoted symmetric division,
thus preventing differentiation. In contrast, Numb expression
drives asymmetric division that could lead to commitment,
differentiation and impairment of BC CML establishment and
propagation.116 The effects of Musashi and Numb may be
mediated through the Notch and p53 pathways.118,119 GSK-3b
can regulate both pathways.
GSK/b-ARRESTIN2 AND CML DEVELOPMENT
Another key component in the establishment of CML is b-arrestin2
(b-arr2).120 b-arr2 is a member of a small family of scaffolding
proteins that regulate G protein-coupled receptor signaling. They
were originally identiﬁed as desensitizers of G protein-coupled
receptor signaling; however, they now have been shown to
transduce signals. The b-arr2 interacts and regulates many signal
transduction pathways that are important in proliferation and
differentiation. The b-arrs have been shown to be important in
regulation of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR
proliferative pathways as well as the Wnt/b-catenin and Hh
developmental pathways.121,122
GSK-3b is a key regulatory molecule essential for b-arr2 complex
formation. GSK-3b stabilizes the b-arr2 complex. Akt normally
inhibits the activity of GSK-3b; Akt can be inhibited by PP2A.
Lithium inhibits GSK-3 by activating Akt.123 In the presence of
activated Akt, GSK-3b is inhibited and the b-arr2 signaling
complex is destabilized. GSK-3b is essential for the effects that
lithium has on mammalian behavioral disorders at least in mice.123
Thus, GSK-3 and b-arr2 could be key targets in leukemia and other
disorders.
Upon analysis of b-arr1 / or b-arr2 / knockout mice, it was
determined that the HSC-enriched cells (c-Kitþ Lin , Sca-1þ
(KLS)) in both b-arr1 / and b-arr2 / null mice were similar to
those present in normal mice, indicating that the establishment of
the hematopoietic compartment was not dependent upon either
functional b-arr1 or b-arr2.120 However, in the b-arr2 / knockout
mice, defects in the functions of the HSCs were observed, as well
as in the frequency of colonies observed after serial replating.
Also, the HSCs from b-arr2 / mice had a decreased ability to
renew and repopulate lethally irradiated recipient mice in
Figure 6. Roles of Musashi and Numb in regulation of asymmetric
and symmetric cell division in BC CML. Chimeric upstream
transcription factors such as NUP98-HOXA9 can induce the Musashi
RNA binding factor that is important in determining cell fate.
Musashi is elevated in BC CML; in contrast, the Numb protein is
detected at low levels in BC CML. The Numb protein plays a key role
in asymmetric cell division and it is usually present in one daughter
cell after division and not the other, allowing different cellular fates.
Numb can regulate many pathways important in BC CML including
Hh, Notch and p53 that can also be regulated by GSK-3. This figure is
presented to provide the reader an idea of the importance of
regulation of asymmetric vs symmetric division in BC CML and how
division can be regulated by Numb and upstream Musashi and
NUP98-HOXA9.
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comparison with HSCs isolated from normal mice. Thus,
long-term HSC renewal was dependent on functional b-arr2
activity under conditions where a high degree of proliferation was
required but not during homeostasis.120
To ascertain whether b-arr2 had a role in leukemia develop-
ment, KLS stem cells were isolated from wild-type, b-arr1 / and
b-arr2 / mice and infected with a virus encoding BCR-ABL
and serially replated in vitro. Fewer colonies were obtained from
the KLS cells obtained from the b-arr2 / mice. Additional
studies were performed in transplant studies in mice. Fewer mice
transplanted with the BCR-ABL-infected KLS cells obtained from
b-arr2 / succumbed to disease. Thus, b-arr2 plays key roles in
the establishment of CML in vitro and in vivo. Additional studies
were performed with BCRABL-infected KLS cells from normal mice
that were transduced with b-arr2 shRNAs or control shRNAs.
Signiﬁcantly fewer colonies were recovered from CML stem cells
transduced with the b-arr2-shRNAs. These studies indicate that
b-arr2 was required for both initiation of CML and growth and
maintenance of the disease. Loss of b-arr2 also resulted in
decreased levels of b-catenin.120
To determine whether b-arr2 had roles in BC CML, BCRABL-
infected KLS cells were infected with the NUP98-HOXA9 oncogene
that results in cells that have properties related to BC CML. NUP98-
HOXA9 is a chromosomal translocation detected in BC CML as well
as in AML.124 The combination of b-arr2 deﬁciency, BCR-ABL and
NUP98-HOXA9 expression decreased primary and secondary
colony formation in vitro as well as establishment of BC CML
in vivo compared with cells from normal and b-arr2-mutant mice.
These results indicated that b-arr2 expression was necessary for
establishment of the more aggressive BC phase of CML.120 Studies
performed with shRNA speciﬁc for b-arr2 indicated that
knockdown of b-arr2 in BCRABL- and NUP98-HOXA9-transduced
BC CML cells resulted in the differentiation of the BC CML cells and
exhaustion of the CML LSC population and impairment in the
disease progression. Loss of b-arr2 reduced activation of b-catenin
and Wnt-related targets in CML and BC CML. Thus, b-arr2 is a
unique molecular target in certain leukemias and potentially
other cancers. These studies indicated that b-arr2 is a key
multifunctional adaptor protein that cooperated with BCRABL
and potentially other oncogenes to induce the CML, and perhaps
other cancers, to become more aggressive.120
WNT/b-CATENIN PATHWAY IN AML
The Wnt/b-catenin pathway has been implicated in AML and is
required for the development of AML LSC.125 The Armstrong
group125 investigated LSCs in mouse models of AML.125 The LSC
AML models were induced either by the coexpression of
the Hoxa9 and Meis1a oncogenes or by the fusion of MLL-AF9
oncogene. The Wnt/b-catenin pathway was required for
self-renewal of LSCs that were derived from either HSCs or more
differentiated GMP cells. The Wnt/b-catenin pathway is normally
active in HSCs but not in more differentiated GMPs. To determine
whether GMPs and LSCs differed in their ability to be transformed
by HoxA9 and Meis1a, the cells were co-transduced with HoxA9
and Meis1a genes and then sorted for KLS cells, which are
enriched with LSCs, and for Lin , c-Kitþ , Sca-1 , FcRgþ ,
CD34þ cells that are enriched with GMP cells. The GMP-HoxA9/
Meis1a cells differed from KLS-HoxA9/Meis1a cells as the
GMP-HoxA9/Meis1a cells rarely developed leukemia in mice,
whereas the KLS-HoxA9/Meis1a did. Similar studies with GMP-
MLL-AF9 cells indicated that they developed leukemia inB70% of
the mice. Some of the in vivo defects in the GMP-HoxA9/Meis1a
cells were examined in recipient mice. Although both KLS-HoxA9/
Meis1a and GMP-HoxA9/Meis1a cells homed to the BM, and both
cell types had heterogeneity in terms of the expression of the
stem cell marker, c-Kit (high and low c-Kit populations), the GMP-
HoxA9/Meis1a cells only maintained the c-Kit-low population for
B1 month after transplantation in mice, whereas the KLS-HoxA9/
Meis1a cells retained the high and low c-Kit populations and
eventually the transplanted mice succumbed from leukemia.
A high frequency of LICs was detected in the c-Kit high
population, whereas a low frequency of LICs was observed in
the cells that expressed low levels of c-Kit. In addition, the GMP/
MLL-AF9 cells were enriched with LSCs. The authors also
investigated some of the genes that were differentially
expressed in normal HSCs, LSCs and normal myeloid progenitor
cells. Cyclooxygenase-1 (Cox1) is also known as prostaglandin G/H
synthase 1 and its gene name is PTGS1. PTGS1 and prostaglandin
receptor (PTGER1) were upregulated in GMP-MLL-AF9 and
KLS-HoxA9/Meis1a-derived L-GMPs.125
There have been previously connections documented between
the Wnt/b-catenin and prostaglandin synthesis pathways.126 The
expression of b-catenin was observed in GMP-MLL-AF9-derived
and KLS-HoxA9/Meis1a-derived L-GMPs but not in normal GMP.
b-Catenin was also not detected in GMP-HoxA9/Meis1a cells.
Activated b-catenin was detected after 1 month in the nucleus
of c-Kit-high but not c-Kit-low cells isolated from mice
injected with KLS-HoxA9/Meis1a. A constitutively active b-catenin
(CTNNB1) gene cooperated with GMP-HoxA9/Meis1a cells to
induce AML as frequently as that observed in KLS-HoxA9/Meis1a
cells. As a control, the ability of the constitutively active b-catenin
(CTNNB1) gene by itself to induce AML was determined and it
did not.125
The effects of indomethacin were determined. Treatment of
LIC-enriched c-Kit-high cells with indomethacin lowered b-catenin
expression in vitro and lowered the expression of b-catenin in
mice injected with the LICs. Indomethacin treatment also lowered
the presence of the c-Kit-high LSC population in mice transplanted
with fully developed MLL-AF9 leukemia. These stunning results
indicated that indomethacin suppressed the LIC population
necessary for the development of AML as well as reduced
established LSCs.125
The role of b-catenin in HoxA9/Meis1a-mediated leukemia
was further examined with b-catenin-deﬁcient KLS cells obtained
from BM of CTNNB1-loxP/loxP mice. KLS-HoxA9/Meis1a,
CTNNB1 loxP/loxP cells were isolated and transduced with
the Cre recombinase or an empty vector. The resulting
KLS-HoxA9/Meis1a, CTNNB1 / cells were injected into mice as
were KLS-HoxA9/Meis1a, CTNNB1-loxP/loxP cells. The KLS-HoxA9/
Meis1a, CTNNB1 / cells lost their ability to expand in mice,
whereas the KLS-HoxA9/Meis1a, CTNNB-loxP/loxP cells expanded in
mouse BM and induced leukemia. Introduction of the
constitutively active CTNNB1 construct allowed the KLS-HoxA9/
Meis1a, CTNNB1 / cells to proliferate.125
Thus, the Wnt/b-catenin pathway was required for Hox-
mediated transformation of HSCs and MLL-AF9-mediated trans-
formation of committed progenitor cells. MLL-AF9 activated
CTNNB1 in GMP to allow transformation. In contrast, there was
normally insufﬁcient b-catenin in normal GMP to permit the HOX
genes to transform GMP. These results by the Armstrong group125
suggest that targeting the Wnt/b-catenin pathway is a therapeutic
approach in AML as the b-catenin is not absolutely required for
the self-renewal of adult HSCs.104,125
ROLES OF GSK-3/WNT/b-CATENIN IN CML AND OTHER
LEUKEMIAS
GSK-3 has also been shown to be a therapeutic target in MLL,
CLL and MM. GSK-3 plays key roles in CML-LSC and may be a
therapeutic target. The ability of CML LSCs to renew has been
linked to Wnt/b-catenin activation as a result of GSK-3b inhibition
or BCR-ABL-mediated phosphorylation of b-catenin. BCR-ABL
phosphorylation of b-catenin impaired the ability of b-catenin to
bind the GSK-3/Axin destruction complex.88,113,127 GSK-3b is
Multifaceted roles of GSK-3 and Wnt
JA McCubrey et al
26
Leukemia (2014) 15 – 33 & 2014 Macmillan Publishers Limited
activated by phosphorylation at Y216 that is located in the
activation loop. This may occur by autophosphorylation or
phosphorylation mediated by PYK2, MEK1 or SRC-family kinases.
b-Catenin is also associated with imatinib resistance in CML.88
Recently, it has been observed that targeting GSK-3b promotes
imatinib-mediated apoptosis in CML LSCs but not normal
HSCs.128 GSK-3b is constitutively phosphorylated on Y216 and
predominantly localized in the cytoplasm in CML stem/progenitor
cells that contrasts with the cytoplasmic/nuclear localization
and activation status of GSK-3b in normal cells. BCR-ABL can
regulate the activation of the Raf/MEK/ERK pathway and Src/
GSK-3b. Imatinib treatment increased GSK-3b activity and
nuclear transport. In contrast, dasatinib, which targets both
BCR-ABL and cytokine-dependent Raf/MEK/ERK pathway and
Src/GSK-3b, did not increase GSK-3b activity and nuclear
transport. These studies revealed that treatment of CML LSCs
with the GSK-3b inhibitor SB216763 and imatinib suppressed CML
LSCs and spared BCR-ABL-negative cells. In contrast, treatment of
CML LSCs with the GSK-3 inhibitor SB216763 and dasatinib did
not suppress CML LSCs. Thus, GSK-3 inhibition primed a
pro-differentiative/pro-apoptotic transcription program in the
nucleus of CML LSCs by regulating the levels of b-catenin, cyclin
D1, c-EBPa, ATF5, mTOR and p27Kip-1.
In the above studies by Reddiconto et al.128, freshly isolated
CML LSCs expressed a constitutively Y216-phophorylated GSK-3b
that could be inhibited by the ATP-competitive GSK-3b inhibitor
SB216763. Inhibition of GSK-3b decreased the pool of b-catenin
that was targeted for proteasomal degradation. Furthermore,
imatinib induced the phosphorylation of GSK-3b at Y216 in a
dose-dependent manner. These studies also indicated that Src
family kinases and Raf/MEK/ERK signaling were upstream
regulators of GSK-3b activity in cytokine-stimulated CML chronic-
phase precursors. GSK-3b was shown to be located primarily in the
cytoplasm and its nuclear levels were reduced in cytokine-
stimulated CML LSCs. In contrast, a diffuse staining of GSK-3b
was observed in normal HSCs, indicating that it was shuttling in
and out of the nucleus. Its translocation may have been aided by
chaperon proteins such as FRAT or tau. In the previously
mentioned studies by Reddiconto et al.128, the nuclear import of
GSK-3b was prevented in a BCR-ABL-dependent mechanism.
Combining GSK-3 inhibitors with imatinib, but not dasatinib,
resulted in changes in the levels of b-catenin, cyclin D1, C/EBPa,
ATF5, mTOR and p27Kip-1 in CML LSCs. The authors have proposed
that targeting of GSK-3b in the presence of imatinib may prime a
differentiation/apoptotic program in CML LSCs. As dasatinib also
inhibited Src and Src-family kinase signaling, it may have
prevented the differentiation/apoptotic program and thus was
ineffective in therapy in this case.
EFFECTS OF GSK-3 IN B-CLL
Inhibition of GSK-3 in B-CLL resulted in epigenetic silencing of
NF-kB target genes and induction of apoptosis as well as
suppression of proliferation.129 GSK-3b positively regulated
NF-kB gene transcription and cell survival. GSK-3 inhibition
resulted in inhibition of NF-kB binding to some of its target
gene promoters (Bcl-2 and X-linked inhibitor of apoptosis (XIAP))
via epigenetic modiﬁcation of histones.
EFFECTS OF GSK-3 IN MULTIPLE MYELOMA
Both GSK-3a and GSK-3b have been determined to be expressed in
multiple myeloma (MM).130,131 GSK-3 inhibition also suppressed MM
proliferation. GSK-3 inhibitor treatment resulted in dephosphorylation
of FOXO-3A and activation of p27Kip-1. In untreated MM cells,
FOXO-3A was highly phosphorylated and inactive.132
Thiadiazolidinone (TDZD) is a noncompetitive inhibitor of
GSK-3. TDZD induced apoptosis in MM cell lines as well as
apoptosis of primary myeloma cells freshly isolated from patients.
In contrast, CD34þ normal hematopoietic cells were protected
from apoptosis after TDZD treatment. The expression of the
pro-apoptotic proteins Fas ligand and I-kBa increased after
TDZD treatment. Other studies have examined the role of GSK-3
inhibitors in MM.130 GSK-3 inhibition arrested MM cell proliferation
and induced apoptosis. MM cell viability was reduced after
treatment with small interfering RNAs for GSK-3b but not for GSK-
3a. Interestingly, inhibition of GSK-3a sensitized the MM cells to
the cytotoxic effects of the proteosome inhibitor bortezomib.
Bortezomib treatment resulted in the nuclear translocation of
S9- and S21-dephosphorylated GSK-3b and GSK-3a respectively.
GSK-3a knockdown resulted in reduced phosphorylation of Akt at
S473. Thus, Akt may regulate GSK-3 and GSK-3 may regulate Akt.
GSK-3 has been proposed to have growth-promoting roles in
MM as it may support their survival as well as favor loss by acting
on the microenvironment. The microenvironment supports MM
growth and also protects against cytotoxic agents. GSK-3 may
phosphorylate the MAF family of transcription factors that
promote proliferation of MM. The MAF family of transcription
factors are important in MM as the three MAF genes have been
shown to be translocated to the IgH locus in MM. Namely, cMAF in
t(16:14), MAFB in t(20;14) and MAFA in t(8:14).133 GSK-3
phosphorylation of MAFA resulted in a reduction of the half-life
of the MAFA transcription factor as it underwent ubiquitin-
dependent proteasomal degradation. However, GSK-3
phosphorylation of MAFA stimulated its transcriptional activity
by enhancing its association with transcriptional co-activators.
These results were conserved with cMAF and MAFB.133 The
transforming ability of MAFA was dependent on GSK-3
phosphorylation. GSK-3 could activate Akt and Mcl-1 that also
resulted in proliferation and survival of MM and sensitivity to
proteosome inhibitors. GSK-3 can also activate NF-kB that has
many effects on proliferation, survival, resistance to chemotherapy
and angiogenesis. In addition, GSK-3 inhibition of the Wnt/b-
catenin pathway could affect the ability of pre-osteoblasts to
differentiate into osteoblasts that affect MM-associated bone
disease. GSK-3 inhibitors were determined to have two different
effects on MM: ﬁrst, they would inhibit the growth of MM and,
second, they would suppress bone disease. Inhibition of GSK-3 by
the BIO inhibitor (6-bromoindirubin-30oxime) reduced the MM-
associated bone disease in a mouse model. BIO induced apoptosis
of MM cells in vitro and, more importantly, BIO improved
osteogenic differentiation and enhanced bone deposition in
mouse studies.134
Additional studies have suggested that GSK-3 plays prosurvival
roles in MM through regulation of noncanonical NF-kB pathway
expression and protein stability.135 Constitutive activation of the
noncanonical NF-kB pathway has been observed in MM. GSK3
may interact with Fbxw7a and regulate the degradation of p100
(NF-kB2), an inhibitor of noncanonical NF-kB signaling. Fbxw7a is
a F-box protein. F-box proteins are the substrate-targeting
subunits of SCF (Skp1/Cul1/F-box protein) ubiquitin ligase
complexes. p100 shuttles between the cytoplasm and nucleus.
p100 is the primary inhibitor of noncanonical NF-kB pathway
by sequestering NF-kB heterodimers in the cytoplasm and
preventing them from being localized in the nucleus and
transcriptionally active. p100 is targeted in the nucleus for
proteasomal degradation by Fbxw7a when p100 is phos-
phorylated by GSK-3. Hence, inhibiting GSK-3 prevents p100
degradation and allows p100 to suppress noncanonical NF-kB
signaling and apoptosis of MM occurs.
GSK-3 INHIBITORS
Previous clinical studies have indicated that lithium had effects on
HSCs and other hematopoietic cells.136 Lithium was determined to
increase circulating HSCs and peripheral blood counts.137 As early
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as 1998, it was proposed that lithium might be used to mobilize
HSCs for BM transplantations.137 An important effect of inhibiting
GSK-3 is stimulation of the Wnt/b-catenin and PI3K/PTEN/Akt/
mTORC1 pathways, although it must be pointed out that GSK-3
has many biological effects.138
Several (more than 50) GSK-3 inhibitors have been developed,
including SB-216763, SB-415286, BIO and AR-A014418.139 GSK-3
inhibitors may be useful in the treatment of certain cancers. Some
studies in colorectal cancer, glioblastoma, pancreatic cancer, MM,
acute lymphocytic leukemia, AML, CLL and ovarian cancer have
suggested that GSK-3 was involved in tumorigenesis. It may be
appropriate to treat these cancers with GSK-3 inhibitors.129
Treatment of the leukemia cell lines KG1a, K562 and CMK with
the GSK-3 inhibitor SB-415286 induced cell growth inhibition,
cell cycle arrest at G2/M, cyclin B downregulation, b-catenin
stabilization, GSK-3b S9 phosphorylation and apoptosis.140 The
authors observed that blocking the death receptor pathway with
an inhibitor of caspase 8 did not neutralize the effects of the
GSK-3 inhibitor. Treatment with the GSK-3 inhibitor resulted in
the depolarization of the mitochondrial membrane potential that
was regulated by the dephosphorylation of Bcl-2 and the
downregulation of Bcl-XL. It is unclear whether the stabilized
b-catenin induced by the treatment of the leukemia cells with
the GSK-3 inhibitor was responsible for the induction of apoptosis
of these cells. This GSK-3 inhibitor (SB-415286) in the above-
mentioned studies as well as arsenic trioxide and LiCl inactiva-
ted GSK-3b in AML (APL) cells by inducing the phosphorylation of
S9 on GSK-3b.141 In contrast, in other cancers such as breast
cancer and medulloblastoma, increased GSK-3 expression was
associated with the induction of apoptosis.142 Thus, it remains
controversial as to whether GSK-3 inhibitors will inhibit or
promote cancer growth.
GSK-3 inhibitors have been isolated and their effects on
pluripotency determined. Most GSK-3 inhibitors are ATP compe-
titive and do not discriminate between GSK-3a and GSK-3b.23 The
1i is a macrocyclic bisindolylmaleimide compound that is a
selective ATP competitive inhibitor of GSK-3. BIO and TWS119 are
additional GSK-3 inhibitors. BIO was determined to be capable of
inhibiting GSK-3 and activating Wnt/b-catenin signaling that
maintained the pluripotency of human and mouse ESCs.102
Sustained GSK-3 inhibition or Wnt pathway activation was sub-
sequently shown to promote ESC differentiation into multipotent
mesendodermal progenitors or their differential progenitors.143
GSK-3 is a key component of the Wnt, Hh and Notch pathways
that can regulate cell-fate determination and maintenance of stem
cells. GSK-3 can phosphorylate the GLI2 transcription factor, a
critical component in the Hh signaling pathway.144
Inhibition of GSK-3 in the presence of leukemia inhibitory factor
and bone morphogenetic protein can enhance the self-renewal of
ESCs in culture systems. The mechanism by which this happens is
not clear. It may occur by preventing the downregulation of
pluripotency factors such as Oct-4 and Nanog. In addition, other
transcription factors associated with pluripotency, such as c-Myc
and c-Jun, are phosphorylated and inactivated by GSK-3. Bone
et al.145 synthesized 48 derivatives of the GSK-3 inhibitor 1i. The
ability of the GSK-3 inhibitors to maintain undifferentiated ESCs
was determined. The effectiveness of these compounds
to maintain undifferentiated ESCs was associated with inhibition
of GSK-3. These results point to the potential of using GSK-3
inhibitors to maintain stem cell pluripotency as well as to expand
these cells. These inhibitors may also prove to be effective with
induced pluripotent stem cell generation.
The GSK-3 inhibitors GSK-3 IX, SB216763 and allsterpaullone
inhibited the growth of human leukemias containing MLL
translocations.36 GSK-3b activity has been shown to be essential
for the maintenance of MLL LSCs but not normal myeloid
progenitors or progenitors transfected with other non-MLL
fusions. In these studies, both GSK-3a and GSK-3b provided
similar functions in terms of regulating the growth of
MLL-transformed leukemias. The authors observed that the cell
cycle regulatory molecule p27Kip-1 was important for the
effectiveness of the GSK-3 inhibitors, as knockdown of p27Kip-1
suppressed the growth arrest of the GSK-3 inhibitors speciﬁcally in
MLL-transformed cells but not fusion protein-transformed cells.
The authors have proposed a model that GSK-3 supports the
maintenance of MLL leukemic cells by promoting p27Kip-1
degradation. In contrast, when the MLL-transformed cells were
treated with the GSK-3 inhibitors, p27Kip-1 accumulated speciﬁcally
in the MLL-transformed cells and cell cycle arrest occurred.
Targeting the Raf/MEK/ERK and PI3K/PTEN/Akt/mTORC1 pathways
will also have effects on GSK-3 activity as GSK-3 interacts with
multiple components of these pathways.146–149 A diagram of
some of the effects of GSK-3 inhibitors is presented in Figure 7.
WNT/b-CATENIN INHIBITORS
Inhibitors to the Wnt signaling pathway have been developed and
are being evaluated.150 Some recent screens have demonstrated
the iron dependence of b-catenin.151 Iron chelation may be an
effective mechanism to inhibit Wnt/b-catenin signaling. Multiple
iron chelators have been developed and some have been
evaluated in clinical trials for other diseases besides cancer.152
Iron chelators inhibit b-catenin stabilization. Acyl hydrazones
bind iron and their chelating activity was required to block the
growth of colorectal cancers that proliferate in response to
increased Wnt/b-catenin signaling. A series of structurally
unrelated iron chelators consisting of desferioxamine, defarasirox
and ciclopirox olamine inhibited Wnt signaling. AML patients
taking ciclopirox olamine had a reduction in the expression of the
Wnt target gene Axin-2. Increases in iron in certain cancers and
growth conditions promoted elevated Wnt/b-catenin signaling,
resulting in tumorigenesis.151 Nonsteroidal anti-inﬂammatory
drugs and the COX-2 inhibitor celecoxib inhibit b-catenin-
dependent transcription in colorectal cancers and other cell
types including leukemia.153
A critical complex to target in this pathway is the b-catenin/TCF
complex. Unfortunately, this complex has been difﬁcult to
effectively target. An alternative approach is to activate natural
inhibitors of this pathway. Inhibitors of Wnt response (IWR-1/2)
have been isolated that target Axin and stabilize it.150 XAV939 is
another Axin activator.154 IWR-1/2 and XAV939 stimulate b-catenin
degradation by inhibiting tankyrase. The stability of Axin1/2 is
regulated by ADP ribosylation that is catalyzed by the enzyme
tankyrase. The turnover of Axin1/2 is regulated by poly-ADP-
ribosylation that is catalyzed by tankyrase (TNKS). Thus, when
tankyrase is inhibited, Axin is stabilized and b-catenin is
destabilized and Wnt signaling is inhibited. The poly-ADP-
ribosylated Axin1/Axin2 proteins are then recognized by
proteins such as ring ﬁnger protein 146 (RNF146) that mediates
their ubiquitination and subsequent degradation.
The stability of b-catenin is also negatively regulated by
phosphorylation by CK1g. Thus, a mechanism to negatively
regulate b-catenin stability is to increase CK1g activity. It has
been recently shown that the FDA (Food and Drug Admini-
stration)-approved drug Pyrvinium activated CK1g and inhibited
the Wnt/b-catenin pathway.154 This was determined by
performing a screen for compounds that could stabilize Axin
and promote b-catenin turnover.
Another approach to inhibit the Wnt/b-catenin pathway is to
block the activity of the enzyme Porc (short for porcupine).67 Porc
is a highly conserved component of the canonical Wnt/b-catenin
pathway. Porc is a transmembrane O-acyltransferase in the
endoplasmic reticulum that is required for Wnt palmitoylation
and maturation.155 Wnt proteins that lack lipids are not secreted.
The IWP2 compound blocked Porc preventing Wnt palmitoylation
and Wnt/b-catenin signaling was suppressed.92 There are
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hydrophobicity problems with the current IWP2 compound;
however, attempts are being made to modify the IWP2
compound or to isolate related compounds that have better
solubility. As Wnt signals are critical for LICs, variations of the IWP2
compound may become important in leukemia therapy.
A comprehensive list of Wnt pathway inhibitors, their modes
of actions and the cancer models they have been examined is
presented in the review by Anastas and Moon.68
SUMMARY
GSK-3a and b are critical enzymes involved in the regulation of
many biological processes. In this review, we have focused more
Figure 7. Effects of targeting GSK-3 in leukemia. Targeting of GSK-3 can interrupt important points in leukemogenesis. (a) Targeting GSK-3
may inhibit the activity of critical transcription factors such as CREB that are important in LICs. (b) Targeting GSK-3 may inhibit suppression of
p27Kip-1, and thus cell cycle arrest will occur. Open p27Kip-1 means degraded protein. (c) It may also be important in certain instances to target
b-catenin with drugs such as indomethacin as b-catenin levels will increase when GSK-3 is inhibited. (d) Inhibiting GSK-3 prevents the
phosphorylation of LRP5/6 that prevents b-catenin stabilization. This figure is provided to elicit the possibility of targeting GSK-3 in leukemia.
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on the effects that GSK-3 has on cancer, but it also has critical
roles in many other physiological processes. Although GSK-3 is
a downstream target of Akt, it can also interact with TSC2
to regulate mTORC1. GSK-3 can also interact with mTORC1
to regulate p70S6K that can indirectly regulate Akt. Thus, GSK-3
has intricate roles in the regulation of signaling pathways. GSK-3
also serves to regulate the Wnt/b-catenin pathway at multiple
levels; in some cases, it inhibits the activity of Wnt/b-catenin
pathway, whereas in other cases it promotes the pathway. This
latter effect is especially prominent in LSCs, where GSK-3 inhibitors
may prove clinically effective; however, they probably will have to
be administered with b-catenin or downstream TCF/LEF inhibitors.
GSK-3 also interacts with the Hh, Notch, Raf/MEK/ERK and other
important regulatory pathways. It is interesting to consider
that inhibiting GSK-3 does not have more dire consequences as
so many pathways will be affected. However, many patients have
been treated with the GSK-3 inhibitor lithium for years without
apparent increases in the cancer incidence. Clearly, GSK-3 is
a kinase with many biochemical effects. Further understanding of
these effects may result in appropriate therapies for certain
leukemias.
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